GoAI
Get started
Teva Pharmaceutical Industries Limited logo

Teva Pharmaceutical Industries Limited

TEVA

NYSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$37.34

+$0.53 · +1.44%

Aug 21, 4:00 PM ET

TEVA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

81

Deep Value

Momentum

51

Neutral

Sentiment

74

Bullish

Risk resilience

67

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
IL

Market position

Day range

Current $37.34

52-week range

Current $37.34

Open
$36.58
Previous close
$36.81
Volume
2.8M
Market cap
43.49B USD
50-day average
$33.8812
+10.21% above average
200-day average
$31.9475
+16.88% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
49.69B USD
P/E (TTM)
57.64×
P/B (TTM)
5.54×
P/S (TTM)
2.47×
EV / EBITDA
15.82×
Earnings yield
3.93%
Free cash flow yield
3.20%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
52.46%
Operating margin
17.11%
Net margin
4.16%
Return on equity
17.83%
Return on assets
3.46%
Return on invested capital
7.41%

Financial health

Debt / equity
2.16×
Current ratio
1.04×
Altman Z-score
0.83
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends59%31%4%-23%Gross margin, FY2021: 47.83%Gross margin, FY2022: 46.72%Gross margin, FY2023: 48.25%Gross margin, FY2024: 48.74%Gross margin, FY2025: 51.79%Operating margin, FY2021: 10.81%Operating margin, FY2022: -14.72%Operating margin, FY2023: 2.73%Operating margin, FY2024: -1.83%Operating margin, FY2025: 12.50%Net margin, FY2021: 2.63%Net margin, FY2022: -16.39%Net margin, FY2023: -3.53%Net margin, FY2024: -9.91%Net margin, FY2025: 8.17%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 47.83%. Gross margin FY2022 46.72%. Gross margin FY2023 48.25%. Gross margin FY2024 48.74%. Gross margin FY2025 51.79%. Operating margin FY2021 10.81%. Operating margin FY2022 -14.72%. Operating margin FY2023 2.73%. Operating margin FY2024 -1.83%. Operating margin FY2025 12.50%. Net margin FY2021 2.63%. Net margin FY2022 -16.39%. Net margin FY2023 -3.53%. Net margin FY2024 -9.91%. Net margin FY2025 8.17%.

Income trends

Revenue

17.26B USD+4.31%

Operating income

2.16B USD+2.46B USD

Net income

1.41B USD+3.05B USD
Income trends across reported periods19.23B USD11.35B USD3.46B USD−4.42B USDRevenue, FY2021: 15.88B USDRevenue, FY2022: 14.93B USDRevenue, FY2023: 15.85B USDRevenue, FY2024: 16.54B USDRevenue, FY2025: 17.26B USDOperating income, FY2021: 1.72B USDOperating income, FY2022: −2.2B USDOperating income, FY2023: 433M USDOperating income, FY2024: −303M USDOperating income, FY2025: 2.16B USDNet income, FY2021: 417M USDNet income, FY2022: −2.45B USDNet income, FY2023: −559M USDNet income, FY2024: −1.64B USDNet income, FY2025: 1.41B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 15.88B USD. Revenue FY2022 14.93B USD. Revenue FY2023 15.85B USD. Revenue FY2024 16.54B USD. Revenue FY2025 17.26B USD. Operating income FY2021 1.72B USD. Operating income FY2022 −2.2B USD. Operating income FY2023 433M USD. Operating income FY2024 −303M USD. Operating income FY2025 2.16B USD. Net income FY2021 417M USD. Net income FY2022 −2.45B USD. Net income FY2023 −559M USD. Net income FY2024 −1.64B USD. Net income FY2025 1.41B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue17.26B USD16.54B USD15.85B USD14.93B USD15.88B USD
Cost of goods sold8.32B USD8.48B USD8.2B USD7.95B USD8.28B USD
Gross profit8.94B USD8.06B USD7.65B USD6.97B USD7.59B USD
Research and development1.01B USD1.06B USD953M USD838M USD1.09B USD
Selling, general, and administrative3.97B USD3.7B USD3.5B USD3.45B USD3.53B USD
Operating expenses6.78B USD8.37B USD7.21B USD9.17B USD5.88B USD
Interest income——68M USD——
Interest expense916M USD941M USD1.03B USD930M USD891M USD
Depreciation and amortization1B USD1.06B USD1.15B USD1.31B USD1.33B USD
Operating income2.16B USD−303M USD433M USD−2.2B USD1.72B USD
Net income1.41B USD−1.64B USD−559M USD−2.45B USD417M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+4.76%
11 comparable reports
Latest EPS result
0.02
Estimate 0.08 · Miss by 75.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.040.70.360.02Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Jan 29, 2025: actual 0.71, estimate 0.69, surprise +2.90%, Beat. Q2 2025, reported May 7, 2025: actual 0.52, estimate 0.47, surprise +10.64%, Beat. Q3 2025, reported Jul 30, 2025: actual 0.66, estimate 0.63, surprise +4.76%, Beat. Q4 2025, reported Nov 5, 2025: actual 0.78, estimate 0.68, surprise +14.71%, Beat. Q1 2026, reported Jan 28, 2026: actual 0.96, estimate 0.65, surprise +47.69%, Beat. Q2 2026, reported Apr 29, 2026: actual 0.53, estimate 0.5, surprise +6.00%, Beat. Q3 2026, reported Jul 29, 2026: actual 0.02, estimate 0.08, surprise -75.00%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 0.73, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.9B4.47B4.03B3.6BQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 29, 2025: actual 4.23B USD, estimate 4.1B USD, surprise +3.03%, Beat. Q2 2025, reported May 7, 2025: actual 3.89B USD, estimate 4.38B USD, surprise -11.19%, Miss. Q3 2025, reported Jul 30, 2025: actual 4.18B USD, estimate 4.36B USD, surprise -4.25%, Miss. Q4 2025, reported Nov 5, 2025: actual 4.48B USD, estimate 4.45B USD, surprise +0.57%, Beat. Q1 2026, reported Jan 28, 2026: actual 4.71B USD, estimate 4.32B USD, surprise +9.13%, Beat. Q2 2026, reported Apr 29, 2026: actual 3.98B USD, estimate 3.79B USD, surprise +5.14%, Beat. Q3 2026, reported Jul 29, 2026: actual 4.14B USD, estimate 4.02B USD, surprise +3.02%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 4.23B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$42.67

14.27% upside
Past 12 months12-month forecastHigh $44.00Average $42.67Low $42.00

Rating distribution

46 ratings
Strong buy00%
Buy2248%
Hold2043%
Sell49%
Strong sell00%

Recent analyst actions

9 institutions
ScotiabankmaintainSector Outperform

TEVA news

zacks.com

TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.

Read source
benzinga.com

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Read source
businesswire.com

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Read source
zacks.com

Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?

Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.

Read source
globenewswire.com

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug…

Read source
reuters.com

Humana agrees not to reference Teva's Israel ties at US drug trial

Health insurer Humana has ‌agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly influence jurors.

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.85

2017 complete year-33.5% since 2013

Corporate action history

Dividend

Ex-dividend Nov 27, 2017

$0.085

Quarterly

Record Nov 28, 2017 · Payment Dec 12, 2017

Dividend

Ex-dividend Aug 25, 2017

$0.085

Quarterly

Record Aug 29, 2017 · Payment Sep 14, 2017

Dividend

Ex-dividend Jun 1, 2017

$0.34

Quarterly

Record Jun 5, 2017 · Payment Jun 22, 2017

Dividend

Ex-dividend Feb 28, 2017

$0.34

Quarterly

Record Mar 2, 2017 · Payment Mar 20, 2017

Dividend

Ex-dividend Dec 1, 2016

$0.34

Quarterly

Record Dec 5, 2016 · Payment Dec 20, 2016

Dividend

Ex-dividend Aug 18, 2016

$0.34

Quarterly

Record Aug 22, 2016 · Payment Sep 8, 2016

TEVA peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding TEVA

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core MSCI EAFE ETF logoiShares Core MSCI EAFE ETFIEFA
Market value
319.62M
Weight
0.16%
AUM
195.14B USD
Expense ratio
0.07%
Price / 1D
$100.85+0.86%
iShares MSCI EAFE ETF logoiShares MSCI EAFE ETFEFA
Market value
151.64M
Weight
0.19%
AUM
79.94B USD
Expense ratio
0.32%
Price / 1D
$108.24+0.83%
Schwab International Equity ETF logoSchwab International Equity ETFSCHF
Market value
99.19M
Weight
0.14%
AUM
69.7B USD
Expense ratio
0.03%
Price / 1D
$28.46+0.85%
iShares MSCI Israel ETF logoiShares MSCI Israel ETFEIS
Market value
93.26M
Weight
10.47%
AUM
898.79M USD
Expense ratio
0.59%
Price / 1D
$122.68+1.28%
iShares MSCI EAFE Growth ETF logoiShares MSCI EAFE Growth ETFEFG
Market value
65.92M
Weight
0.39%
AUM
17.17B USD
Expense ratio
0.34%
Price / 1D
$125.7+0.76%
First Trust WCM International Equity ETF logoFirst Trust WCM International Equity ETFWCMI
Market value
61.69M
Weight
3.30%
AUM
1.89B USD
Expense ratio
0.85%
Price / 1D
$19.80+0.81%
iShares Core MSCI Total International Stock ETF logoiShares Core MSCI Total International Stock ETFIXUS
Market value
60.24M
Weight
0.10%
AUM
60.91B USD
Expense ratio
0.07%
Price / 1D
$97.945+0.76%
State Street SPDR Portfolio Developed World ex-US ETF logoState Street SPDR Portfolio Developed World ex-US ETFSPDW
Market value
50.41M
Weight
0.12%
AUM
41.92B USD
Expense ratio
0.03%
Price / 1D
$52.02+0.79%

Continue in GoAI

Research TEVA

research.disclaimer